Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : SI International Ope' Stock Picking Contest -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (2429)	12/12/1998 11:21:00 PM
From: Guy	Read Replies (1) \| Respond to of 2640

re:SNRS? from what i know of them, they are into hyperopic laser correction, a niche market within a niche market, and one where VISX just received approval. Not looking good, True VISX just received approval,however,Unlike other laser procedure which actually cut the eye, SNRS's LTK shapes the underlying cartilage without having to touch the eye. Recovery is rapid,and patients are very satisfied. Approximately 200 million people in the Americas and Western Europe are candidates for this procedure. Good management also runs the company and understands the industry. Also, the laser equipment SNRS uses is much less costly then the VISX model, and requires much less training. People in the OPT. field have invested quite a bit in SNRS due to their positive reaction of the procedure. Guy